Źródła komórek macierzystych krwiotworzenia dla potrzeb transplantacji

• Authors: Piotr Rzepecki , Krzysztof Gawroński , Beata Młot , Sylwia Oborska , Wojciech Pielichowski , Anna Waśko-Grabowska

Title variants

EN

Sources of hematopoietic stem cells for transplantation

• Languages of publication: EN PL

Abstracts

EN

Bone marrow transplantation dates back to the ‘50s, but greatest progress in this therapeutic modality applied successfully in the treatment of several conditions took place mostly during the past 25 years. Among all organ transplantations, bone marrow transplants are second only to kidney transplants. In Poland this therapeutic technique also undergoes a rapid development. During the past 10 years, absolute numbers of various forms of transplantation increased 100-fold, starting from 6 procedures in 1989 to over 700 at present. Essentially, the term bone marrow transplantation (BMT), present in names of international associations and registers, is in fact a colloquialism (e.g. European Group for Blood and Marrow Transplantation). A much more appropriate term would be hematopoietic cell transplantation (HCT). This is because progenitor cells for transplantation may be obtained not only from bone marrow, but also from peripheral blood and umbilical cord blood. The term hematopoietic cell transplantation has a much broader meaning and includes: classic transplantation of bone marrow obtained at surgery, transplantation of peripheral blood stem cells (PBSCT) and umbilical cord blood-derived stem cells. All hematopoietic stem cells express on their surface the CD34+ antigen and glycosylated transmembrane protein, a member of the family of adhesion molecules. In healthy persons, expression of this antigen in bone marrow cells is at the level of 1-3%, while in peripheral blood – 0.01-0.1%, and in umbilical cord blood – 0.1-0.4%. The first source (transplantation material) of hematopoietic progenitor cells was bone marrow, while transplantation of stem cells obtained from peripheral blood and umbilical cord blood started much later (during the ‘80s of the past century).

Keywords

EN

bone marrow; czynniki wzrostu; growth factors; hematopoietic stem cells transplantation; krew obwodowa; krew pępowinowa; mobilizacja komórek macierzystych krwiotworzenia; mobilization of hematopoietic stem cells; peripheral blood; przeszczepianie krwiotwórczych komórek macierzystych; szpik kostny; umbilical cord blood

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Communications
• Journal: Current Gynecologic Oncology
• Year: 2011
• Volume: 9
• Issue: 3
• Pages: 186-198

Contributors

author

Piotr Rzepecki

• Ośrodek Przeszczepiania Szpiku Kliniki Onkologii, Wojskowy Instytut Medyczny. Kierownik Ośrodka Przeszczepiania Szpiku CSK MON WIM: prof. nadzw. dr hab. n. med. Piotr Rzepecki. Prof. nadzw. dr hab. n. med. Piotr Rzepecki, ul. Szaserów 128, 04-141 Warszawa, tel./faks: 22 681 65 59, 22 610 30 98

author

Krzysztof Gawroński

• Ośrodek Przeszczepiania Szpiku Kliniki Onkologii, Wojskowy Instytut Medyczny. Kierownik Ośrodka Przeszczepiania Szpiku CSK MON WIM: prof. nadzw. dr hab. n. med. Piotr Rzepecki

author

Beata Młot

• Ośrodek Przeszczepiania Szpiku Kliniki Onkologii, Wojskowy Instytut Medyczny. Kierownik Ośrodka Przeszczepiania Szpiku CSK MON WIM: prof. nadzw. dr hab. n. med. Piotr Rzepecki

author

Sylwia Oborska

• Ośrodek Przeszczepiania Szpiku Kliniki Onkologii, Wojskowy Instytut Medyczny. Kierownik Ośrodka Przeszczepiania Szpiku CSK MON WIM: prof. nadzw. dr hab. n. med. Piotr Rzepecki

author

Wojciech Pielichowski

• Ośrodek Przeszczepiania Szpiku Kliniki Onkologii, Wojskowy Instytut Medyczny. Kierownik Ośrodka Przeszczepiania Szpiku CSK MON WIM: prof. nadzw. dr hab. n. med. Piotr Rzepecki

author

Anna Waśko-Grabowska

• Ośrodek Przeszczepiania Szpiku Kliniki Onkologii, Wojskowy Instytut Medyczny. Kierownik Ośrodka Przeszczepiania Szpiku CSK MON WIM: prof. nadzw. dr hab. n. med. Piotr Rzepecki

References

• 1. Hansz J.: Przeszczepianie szpiku kostnego ze wskazań hematologicznych u dorosłych. Postępy Nauk Med. 1993: 6: 175-179.
• 2. Ljungman P., Urbano-Ispizua A., Cavazzana-Calvo M. i wsp.; European Group for Blood and Marrow: Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant. 2006: 37: 439-449.
• 3. Johnsen H.E., Lanza F., Fruehauf S. i wsp.: Sources and procurement of HSC. W: Apperley J.F., Carreras E., Gluck-man E. i wsp. (red.): Haemopoietic Stem Cell Transplantation. Forum Service Editore, Genoa 2004: 79-91.
• 4. Urbano-Ispizua A., Schmitz N., de Witte T. i wsp.; European Group for Blood and Marrow Transplantation: Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant. 2002: 29: 639-646.
• 5. Tarach J.S.: Hematopoetyczne komórki macierzyste szpiku kostnego i antygen Cd34. Acta Haematol. Pol. 1999; 30: 225-233.
• 6. Leung A.Y.H., Kwong Y.L.: Haematopoietic stem cell transplantation: current concepts and novel therapeutic strategies. Br. Med. Bull. 2010; 93: 85-103.
• 7. Koumakis G., Vassilomanolakis M., Barbounis V i wsp.: Optimal timing (preemptive versus supportive) of granulocyte colony-stimulating factor administration following high-dose cyclophosphamide. Oncology 1999; 56: 28-35.
• 8. Kröger N., Renges H., Sonnenberg S. i wsp.: Stem cell mobilisation with 16 μg/kg vs 10 μg/kg of G-CSF for allogeneic transplantation in healthy donors. Bone Marrow Transplant. 2002; 29: 727-730.
• 9. Bensinger W, DiPersio J.F., McCarty J.M.: Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant. 2009; 43: 181-195.
• 10. Arbona C., Prosper F., Benet I. i wsp.: Comparison between once a day w twice a day G-CSF for mobilization of peripheral blood progenitor cells (PBPC) in normal donors for allogeneic PBPC transplantation. Bone Marrow Transplant. 1998; 22: 39-45.
• 11. Armitage S., Hargreaves R., Samson D. i wsp.: CD34 counts to predict the adequate collection of peripheral blood progenitor cells. Bone Marrow Transplant. 1997; 20: 587- 591.
• 12. Reddy R.L.: Mobilization and collection of peripheral blood progenitor cells for transplantation. Transfus. Apher. Sci. 2005; 32: 63-72.
• 13. Hill Q.A., Buxton D., Pearce R. i wsp.: An analysis of the optimal timing of peripheral blood stem cell harvesting following priming with cyclophosphamide and G-CSF. Bone Marrow Transplant. 2007; 40: 925-930.
• 14. Ketterer N., Salles G., Raba M. i wsp.: High CD34+ cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood 1998; 91: 3148-3155.
• 15. Kopf B., De Giorgi U., Vertogen B. i wsp.: A randomized study comparing filgrastim versus lenograstim versus mol-gramostim plus chemotherapy for peripheral blood progenitor cell mobilization. Bone Marrow Transplant. 2006; 38: 407-412.
• 16. Decleva E., Cramer R., Zabucchi G.: Glycosylation improves the priming effect exerted by recombinant human granulocyte colony-stimulating factor (lenograstim) on human neutrophil superoxide production. Int. J. Tissue React. 1995; 17: 191-198.
• 17. Ataergin S., Arpaci F., Turan M. i wsp.: Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation. Am. J. Hematol. 2008; 83: 644-648.
• 18. Villalón L., Odriozola J., Larafia J.G. i wsp.: Autologous peripheral blood progenitor cell transplantation with <2x106 CD34+/kg: an analysis of variables concerning mobilisation and engraftment. Hematol. J. 2000; 1: 374-381.
• 19. Gandhi M.K., Jestice K, Scott M.A. i wsp.: The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. Bone Marrow Transplant. 1999; 23: 9-13.
• 20. Scheid C., Draube A., Reiser M. i wsp.: Using at least 5x106/kg CD34+ cells for autologous stem cell transplantation significantly reduces febrile complications and use of antibiotics after transplantation. Bone Marrow Transplant. 1999; 23: 1177-1181.
• 21. Sohn S.K., Kim J.G., Kim D.H. i wsp.: Impact of transplanted CD34+ cell dose in allogeneic unmanipulated peripheral blood stem cell transplantation. Bone Marrow Transplant. 2003; 31: 967-972.
• 22. Mohty M., Bilger K, Jourdan E. i wsp.: Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation. Leukemia 2003; 17: 869-875.
• 23. Harousseau J.L., Moreau P.: Autologous hematopoietic stem-cell transplantation for multiple myeloma. N. Engl. J. Med. 2009; 360: 2645-2654.
• 24. Clark R.E., Brammer C.G.: Previous treatment predicts the efficiency of blood progenitor cell mobilisation: validation of a chemotherapy scoring system. Bone Marrow Transplant. 1998; 22: 859-863.
• 25. Micallef I.N., Apostolidis J., Rohatiner A.Z. i wsp.: Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin’s lymphoma. Hematol. J. 2000; 1: 367-373.
• 26. Pavone V, Gaudio F., Console G. i wsp.: Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation. Bone Marrow Transplant. 2006; 37: 719-724.
• 27. Tomblyn M., Burns L.J., Blazar B. i wsp.: Difficult stem cell mobilization despite adequate CD34+ cell dose predicts shortened progression free and overall survival after autologous HSCT for lymphoma. Bone Marrow Transplant. 2007; 40: 111-118.
• 28. Bolwell B.J., Pohlman B., Rybicki L. i wsp.: Patients mobilizing large numbers of CD34+ cells (‘super mobilizers’) have improved survival in autologous stem cell transplantation for lymphoid malignancies. Bone Marrow Transplant. 2007; 40: 437-441.
• 29. Urbano-Ispizua A.: Stem cell product for allo-SCT. Tenth ESH-EBMT Training Course on Haemopoietic Stem Cell Transplantation; 24-28.05.2006 r., Warszawa, Polska, materiały zjazdowe.
• 30. Stiff P., Micallef I., McCarthy P. i wsp.: Treatment with plerixafor in non-Hodgkin’s lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient. Biol. Blood Marrow Transplant. 2009; 15: 249-256.
• 31. Calandra G., McCarty J., McGuirk J. i wsp.: AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin’s lymphoma, Hodgkin’s disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant. 2008; 41: 331-338.
• 32. Devine S.M., Vij R., Rettig M. i wsp.: Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 2008; 112: 990-998.
• 33. Pusic I., Jiang S.Y., Landua S. i wsp.: Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol. Blood Marrow Transplant. 2008; 14: 1045-1056.
• 34. Cashen A., Lopez S., Gao F. i wsp.: A phase II study of plerixafor (aMd3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma. Biol. Blood Marrow Transplant. 2008; 14: 1253-1261.
• 35. Hart C., Grassinger J., Andreesen R., Hennemann B.: EPO in combination with G-CSF improves mobilization effectiveness after chemotherapy with ifosfamide, epirubicin and etoposide and reduces costs during mobilization and transplantation of autologous hematopoietic progenitor cells. Bone Marrow Transplant. 2009; 43: 197-206.
• 36. Watts M.J., Ings S.J., Flynn M. i wsp.: Remobilization of patients who fail to achieve minimal progenitor thresholds at the first attempt is clinically worthwhile. Br. J. Haematol. 2000; 111: 287-291.
• 37. Seshadri T., Al-Farsi K, Stakiw J. i wsp.: G-CSF-stimulated BM progenitor cells supplement suboptimal peripheral blood hematopoietic progenitor cell collections for auto transplantation. Bone Marrow Transplant. 2008; 42: 733-737.
• 38. Chiang K.Y., Worthington-White D.: The clinical significance of different hematopoietic stem cell sources (primed marrow, mobilized blood, and steady-state marrow) in autologous and allogenic transplantation. Exp. Hematol. 2004; 32: 698-699.
• 39. Elfenbein G.J., Sackstein R., Oblon D.J.: Do G-CSF mobilized, peripheral blood-derived stem cells from healthy, HLA-identical donors really engraft more rapidly than do G-CSF primed, bone marrow-derived stem cells? No! Blood Cells Mol. Dis. 2004; 32: 106-111.
• 40. Chen Y., Huang X., Xu L. i wsp.: A pilot study of G-CSF mobilized allogeneic bone marrow cells plus peripheral blood stem cells transplantation for malignant hematological diseases. Zhonghua Yi Xue Za Zhi 2002; 82: 1306-1309.
• 41. Ji S.Q., Chen H.R., Wang H.X. i wsp.: Comparison of outcome of allogeneic bone marrow transplantation with and without granulocyte colony-stimulating factor (lenograstim) donor-marrow priming in patients with chronic myelogenous leukemia. Biol. Blood Marrow Transplant. 2002; 8: 261-267.
• 42. Ji S.Q., Chen H.R., Xun C.Q. i wsp.: The effect of G-CSF-stimulated donor marrow on engraftment and incidence of graft-versus-host disease in allogeneic bone marrow transplantation. Clin. Transplant. 2001; 15: 317-323.
• 43. Ostronoff M., Ostronoff F., Souto Maior P. i wsp.: Pilot study of allogeneic G-CSF-stimulated bone marrow transplantation: harvest, engraftment, and graft-versus-host disease. Biol. Blood Marrow Transplant. 2006; 12: 729-733.
• 44. Sanberg P.R., Willing A.E., Garbuzova-Davis S. i wsp.: Umbilical cord blood-derived stem cells and brain repair, Ann. N. Y. Acad. Sci. 2005; 1049: 67-83.
• 45. Ballen K.K.: New trends in umbilical cord blood transplantation. Blood 2005; 105: 3786-3792.
• 46. Urbanowska E., Jędrzejczak WW: Krew pępowinowa jako źródło komórek krwiotwórczych do przeszczepienia. Acta Haematol. Pol. 2004; 35 supl. 1: 87-94.
• 47. Jaroscak J., Goltry K., Smith A. i wsp.: Augmentation of umbilical cord blood (UCB) transplantation with ex vivoexpanded UCB cells: results of a phase 1 trial using the Aas-tromReplicell system. Blood 2003; 101: 5061-5067.
• 48. Korycka A., Robak T: Komórki macierzyste krwi pępowinowej - nadzieje i rzeczywistość. Acta Haematol. Pol. 2005; 36: 389-398.
• 49. He X., Gonzalez V, Tsang A. i wsp.: Differential gene expression profiling of CD34+ CD133+ umbilical cord blood hematopoietic stem progenitor cells. Stem Cells Dev. 2005; 14: 188-198.

• Document Type: article